| ABMR | antibody-mediated rejection |
| ACEis | angiotensin-converting enzyme inhibitors |
| ACR | acute T-cell-mediated rejection |
| AI | artificial intelligence |
| AR | acute rejection |
| ARBs | angiotensin II receptor blockers |
| CAD | chronic allograft dysfunction |
| CDSSs | clinical decision support systems |
| CKD | chronic kidney disease |
| CNIs | calcineurin inhibitors |
| CNPq | National Council for Scientific and Technological Development |
| CR | chronic rejection |
| CV | cardiovascular |
| ddcfDNA | donor-derived cell-free DNA |
| DGF | delayed graft function |
| DM | diabetes mellitus |
| DSAs | donor-specific antibodies |
| eGFR | estimated glomerular filtration rate |
| HERs | electronic health records |
| EndMT | endothelial to Mesenchymal Transition |
| ESKD | end-stage kidney disease |
| EV | extracellular vesicles |
| GDF-15 | growth differentiation factor-15 |
| HF | heart failure |
| IF/TA | interstitial fibrosis/tubular atrophy |
| IL-6 | interleukin-6 |
| IRI | ischemia–reperfusion injury |
| KIM-1 | kidney injury molecule |
| KTx | kidney transplantation |
| MCP-1 | monocyte chemoattractant protein-1 |
| MFI | mean fluorescence intensity |
| MRA | mineralocorticoid receptor antagonist |
| NGAL | neutrophil gelatinase-associated lipocalin |
| Pmp | per million population |
| RRT | renal replacement therapy |
| SGLT2is | sodium-glucose transport 2 inhibitors |
| suPAR | soluble receptor of urokinase plasminogen activator |
| TLR-4 | soluble Toll-like receptor 4 |
| TNFR-1 | Tumor necrosis factor receptor 1 |
| TNFR-2 | Tumor necrosis factor receptor 2 |
| T2DM | type 2 Diabetes Mellitus |
| USA | United States of America |
| UACR | urine albumin-to-creatinine ratio |
| uNAG | urinary N-acetyl-β-D-glucosaminidase |